Peptide
IGF-1 LR3
SaveA modified form of IGF-1 with an arginine substitution at position 3 and a 13-amino-acid extension, giving it a much longer half-life and reduced binding-protein affinity.
Quick verdict
Research reagent commonly used in cell culture. Not approved for human use. Extreme potency and prolonged activity amplify all IGF-1 risks.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Standard cell-culture tool. No clinical trials. Widely used illicitly in bodybuilding. Pharmacologic potency is several-fold higher than native IGF-1.
Benefits
- Extended half-life reduces dosing frequency in research
- Potent anabolic activity in cell-culture models
Dosage notes
No validated human dosing. Research use only. Bodybuilding forums cite 20–100 mcg but this is not medically validated.
Side effects
- Severe hypoglycemia
- Organ growth with chronic use
- Theoretical cancer promotion
- Injection-site reactions
Who should be cautious
Extreme hypoglycemia risk. Prolonged activity compared to native IGF-1. No quality control for gray-market products.
What this page cannot tell you
Zero clinical data. All use is extrapolated from in-vitro pharmacology and anecdotal bodybuilding reports.
Leaderboard scores
- Muscle45
Write a review
Sign in to write a review.